Silibinin inhibits translation initiation: implications for anticancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Silibinin is a flavonoid known for its anticancer properties.
• Its precise molecular mechanisms against cancer, particularly breast cancer, require further elucidation.

Purpose of the Study:

• To investigate the antiproliferative effects of silibinin on MCF-7 breast cancer cells.
• To elucidate the molecular mechanisms underlying silibinin's action, focusing on protein synthesis and translation initiation.

Main Methods:

• MCF-7 breast cancer cells were exposed to varying concentrations of silibinin.
• Global protein synthesis, eukaryotic initiation factor 4F complex levels, and polysome profiles were analyzed.
• Mammalian target of rapamycin (mTOR) signaling pathway activity was assessed.

Main Results:

• Silibinin demonstrated a concentration-dependent antiproliferative effect on MCF-7 cells.
• Global protein synthesis and eukaryotic initiation factor 4F complex levels were reduced.
• Polysome content decreased, impacting cyclin D1 mRNA translation.
• Silibinin inhibited the mTOR signaling pathway upstream of TSC2.

Conclusions:

• Silibinin inhibits breast cancer cell proliferation by suppressing global protein synthesis and translation initiation.
• The mechanism involves the inhibition of the mammalian target of rapamycin (mTOR) signaling pathway.
• These findings provide a molecular basis for silibinin's potential as an anticancer agent.